Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications

Growth factors of the bombesin/gastrin releasing peptide (BN/GRP) family play a critical role in proliferation and progression of malignancies. Inhibitors targeting GRP signalling have been developed and tested as anticancer compounds showing promising preclinical and early phase clinical results. I...

Full description

Saved in:
Bibliographic Details
Published inCurrent drug targets Vol. 17; no. 5; p. 508
Main Authors Laukkanen, Mikko O, Castellone, Maria Domenica
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.04.2016
Subjects
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Bombesin - analogs & derivatives
Bombesin - pharmacology
Bombesin - therapeutic use
Clinical Trials as Topic
Female
Gastrin-Releasing Peptide - metabolism
Humans
Indoles - pharmacology
Indoles - therapeutic use
Male
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplasms - metabolism
Peptide Fragments - pharmacology
Peptide Fragments - therapeutic use
Receptors, Bombesin - antagonists & inhibitors
Signal Transduction - drug effects
Online AccessGet more information

Cover

More Information
Summary:Growth factors of the bombesin/gastrin releasing peptide (BN/GRP) family play a critical role in proliferation and progression of malignancies. Inhibitors targeting GRP signalling have been developed and tested as anticancer compounds showing promising preclinical and early phase clinical results. In this review, we will discuss the molecular signaling, expression and the functional role of BN/GRP-GRPR in different cancer models and will focus on the available strategies to target BN/GRP-GRPR in cancer treatment as well as in tumour diagnosis and follow up.
ISSN:1873-5592
DOI:10.2174/1389450116666151001112130